Highlights Clinuvel Pharmaceuticals Limited

Equities

CUV

AU000000CUV3

Market Closed - Australian S.E. Other stock markets 11:40:14 09/05/2024 am IST			5-day change	1st Jan Change
14.91 ^AUD	-3.62%		+0.34%	-6.81%

29/04	Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3%	MT
14/03	Clinuvel Pharmaceuticals Launches Share Buyback Program	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3%	29/04	MT
Clinuvel Pharmaceuticals Launches Share Buyback Program	14/03	MT
Clinuvel Pharmaceuticals Limited announces an Equity Buyback for 1,500,000 shares, representing 2.99% of its issued share capital.	14/03	CI
Clinuvel Pharmaceuticals Limited authorizes a Buyback Plan.	14/03	CI
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	22/02	CI
Ex-dividend day for final dividend	05/23/05	FA
Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023	29/23/29	CI
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	29/23/29	CI
Clinuvel Pharmaceuticals Secures Supply Contract for Porphyria Medication with the US Department of Veterans Affairs	26/23/26	MT
Clinuvel Pharmaceuticals Secures Patents for Melanocortins for Treatment of Central Nervous System Disorders	14/23/14	MT
Clinuvel Pharmaceuticals Limited Announces Technical Note - CUV803 Study and AIS	20/23/20	CI
Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with PRENUMBRA Instant	20/23/20	CI
Clinuvel Pharmaceuticals Limited Present DNA Repair Data At American Academy of Dermatology Meeting	17/23/17	CI
Clinuvel Pharmaceuticals Launches Skin Protection Product	01/23/01	MT
Clinuvel Launches Cyacle, Next Generation Solar Care	01/23/01	CI
CLINUVEL Launches First Dermatocosmetic Product	01/23/01	CI
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/23/24	CI
Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant	15/23/15	CI
Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation	02/23/02	CI
Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance	23/23/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Clinuvel Pharmaceuticals Limited

Equities

CUV

AU000000CUV3

Highlights

Filters